China cell therapy developer raises $75m
Iaso Biotherapeutics, a Chinese cell therapy developer focusing on oncology treatments, has raised nearly CNY 500m (USD 75m) in an extended Series C round.
Eleven local investors took part in this round, including Shanghai Guoxin Investment & Development, Efung Capital, Shanghai Waigaoqiao Free Trade Zone Group, Nanjing Jiangbei New Area State-owned Asset...
More on Greater China
Latest News
HKEX relaxes rules for IPOs by pre-profit tech companies
The Hong Kong Stock Exchange (HKEX) has loosened its listing requirements to allow pre-profit technology companies to go public with market capitalisations as low as HKD 6bn (USD 764m).
Asia GPs must get smarter on target selection, costs - Bain & Co
Careful target selection – based on geography and sector – and increased emphasis on cost controls during ownership will be critical factors for Asian private equity investors as the industry braces for a downturn, according to Bain & Company.
Longreach buys Japan healthcare SaaS player
North Asia buyout specialist The Longreach Group has invested an undisclosed sum in Wellness Communications Corporation (WCC), a Japanese healthcare software-as-a-service (SaaS) provider.
Asia-Europe investor AGIC supports Danish electronics buyout
AGIC Capital, a specialist in Europe-China cross-border deals, has backed the acquisition of PR Electronics, a Danish manufacturer of signal processing equipment with an existing base in China.